

Intellectual Property Prospector

IP Assets Owned by Firms in Transition

March 19, 2007
Volume 2, Number 12
Prospector Profiles in this Issue

Company Name	Reference Number	Category Profile
Ainsworth Lumber Co. Ltd.	07.0343	Low Rating
American Biophysics Corporation	07.0344	IP Asset Sale
AmeriChip International, Inc.	07.0345	Audit Concerns
Aphton Corporation	07.0346	IP Asset Sale
Axcess International, Inc.	07.0347	Audit Concerns
Brightec, Inc.	07.0348	Audit Concerns
California News Tech	07.0349	Audit Concerns
Dalrada Financial Corp.	07.0350	Loss/Deficit
Dobson Communications Corp.	07.0351	Low Rating
Elan Corporation PLC	07.0352	Loss/Deficit
Emisphere Technologies, Inc.	07.0353	Loss/Deficit
Furniture Brands International, Inc.	07.0354	Covenant Problems
GTC Biotherapeutics, Inc.	07.0355	Loss/Deficit
Headliners Entertainment Group, Inc.	07.0356	Bankruptcy
Human Genome Science, Inc.	07.0357	Loss/Deficit
Innuity, Inc.	07.0358	Audit Concerns
Insmmed, Inc.	07.0359	Restructuring
iSECUREtrac Corp.	07.0360	Loss/Deficit
IsoRay, Inc.	07.0361	Audit Concerns
Jag Media Holdings, Inc.	07.0362	Audit Concerns
Medirect Latino, Inc.	07.0363	Audit Concerns
Micromem Technologies, Inc.	07.0364	Audit Concerns
Oncolytics Biotech, Inc.	07.0365	Loss/Deficit
Pinnacle Foods Group, Inc.	07.0366	Low Rating
Platinum Corporation	07.0367	Audit Concerns
Proxymed, Inc.	07.0368	Audit Concerns
Rigel Pharmaceuticals, Inc.	07.0369	Loss/Deficit

(Click on Reference Number to go directly to Company Profile)

Company Name	Reference Number	Category Profile
Santarus, Inc.	07.0370	Loss/Deficit
Smurfit-Stone Container Corp.	07.0371	Low Rating
Solutia, Inc.	07.0372	Section 363 Sales
Sun Healthcare Group, Inc.	07.0373	Low Rating
Tapestry Pharmaceuticals, Inc.	07.0374	Loss/Deficit
Viropro, Inc.	07.0375	Audit Concerns
WR Grace & Company	07.0376	Loss/Deficit
Yarraman Winery, Inc.	07.0377	Audit Concerns

(Click on Reference Number to go directly to Company Profile)

Intellectual Property Prospector identifies companies with total assets of any size filing for bankruptcy or reporting other financial difficulty and profiles their ownership of intellectual property. The Prospector features companies that meet strictly defined, predetermined criteria and is designed to support the efforts of firms and individuals interested in identifying opportunities in the specific area of intellectual property, which includes patents, trademarks, trade secrets, and licenses, among others. Information is compiled weekly and the Prospector is distributed by email every Sunday evening to arrive before 9:00AM every Monday. The Prospector is published by Beard Group, Inc. (<http://BeardGroup.com>). For subscription information call Customer Service at 240-629-3300, ext. 27.

Prospector Profile Selection Criteria:

In order to appear in the **Intellectual Property Prospector**, a company must report ownership of intellectual property assets, as well as one of the conditions listed below:

- An event which indicates financial distress; e.g., default, distressed exchange offer, preferred dividend omission, debt at deep discount, restructuring, low rating, audit concerns, covenant problems, and loss/deficit.
- Chapter 11, 7, or 15 bankruptcy filing
- Section 363 Sales

DISCLAIMER: The conditions for inclusion in the Prospector are selected by the editors, because, in their opinion, the occurrence of such an event or the existence of such a circumstance is a likely indicator of current or prospective financial or operating difficulty. There are, however, other reasons why such facts or circumstances may exist. The inclusion of a profile suggests the possibility of financial distress or the possibility that the company may be of interest to firms and individuals interested in identifying intellectual property for some other reason. *Inclusion should not be construed to represent analysis of the condition of the company or its intellectual property or a definitive determination that the company is in difficulty.*

ACCURACY & COVERAGE: The information contained herein is obtained from sources believed to be reliable. However, the accuracy of most data cannot be verified prior to publication, and the information is not guaranteed. Desired information is often incomplete, inaccurate, delayed or unavailable. Do not rely on the Prospector without independent verification.

SUBSCRIPTIONS: Subscription rate: \$575 for six months, payable in advance. All subscriptions entered are continued until canceled. For subscription information call Customer Service at (240) 629-3300, ext. 27.

Intellectual Property Prospector is a publication of **Beard Group, Inc.**, P. O. Box 4250, Frederick, MD 21705, (240) 629-3300, <http://www.beardgroup.com>. ISSN 1935-3901. Copyright 2007. All rights reserved. Publisher: Christopher Beard.

**Prospector
Profile
07.0343**

Ainsworth Lumber Co. Ltd.

1055 Dunsmuir Street, Suite 3194
Vancouver, British Columbia V7X 1L3
Canada
(604) 661-3200

NAICS		423310
Employees		1,700
Revenue	(mil)	\$1,248.23
Income	(mil)	\$153.15
Assets	(mil)	\$1,513.00
Liability	(mil)	\$1,097.83
(for the year ended 12/31/2005)		

Category: Low Rating

Event: Standard & Poor's Ratings Services lowered the long-term corporate credit and senior unsecured debt ratings of Ainsworth Lumber Co. Ltd. from 'B' to 'CCC+'. The rating agency also removed the ratings from CreditWatch with negative implications. The rating outlook is negative. Standard & Poor's analyst Donald Marleau said that the Company has experienced a significant cash drain, as the market conditions of its primary product remained very weak. The rating agency said that the Company's liquidity deteriorated in the past year, especially in the most recent quarter.

Intellectual Property: The Company focuses its research and development efforts on improving manufacturing efficiencies, evaluating the suitability of potential wood resources, and developing new or improved products designed to expand the offering of its AinsworthEngineered® OSB and specialty plywood products, including Pourform® brands of concrete forming products. The Company conducts proprietary research in various research institutions, while also carrying out trials at manufacturing facilities, and relying on the expertise of a number of key suppliers. The Company owns several trademarks, trade names and patents in connection with its OSB and specialty plywood products. [SEC Filing 20-F 04-17-06]

Description: The Company and its subsidiaries produce lumber and wood products such as plywood, lumber, and flooring.

Officers: Brian Ainsworth (Chair & CEO); D. Allen Ainsworth (Pres.); Catherine E. Ainsworth (COO & Sec.); Robert Allen (CFO); D. Michael Ainsworth (EVP); Ron B. Anderson (Dir.); Doug B. Buchanan (Dir.); K. Gordon Green (Dir.); Morley Koffman (Dir.); W. Gordon Lancaster (Dir.); David Ainsworth (Dir.); Susan Ainsworth (Dir.)

Auditor: Deloitte & Touche LLP

Securities: Common Stock Symbol ANS.TO; TSX;
14,649,140 common shares outstanding as of December 31, 2006.

[Return to top](#)

***Prospector
Profile
07.0344***

American Biophysics Corporation

140 Frenchtown Rd.
North Kingstown, RI 02852
(401) 884-3500

NAICS	541710
Employees	70

Category: IP Asset Sale

Event: American Biophysics Corp. is selling its assets including propriety technology, US and international patents, inventory, machinery, equipment, computer systems, and customer database.

Interested parties may contact the receiver at:

Jonathan N. Savage, Receiver
Shechtman, Halperin, Savage, LLP
1080 Main Street
Pawtucket, RI 02860
Tel: (410) 272-1400
Fax: (401) 272-1403
<http://www.shslawfirm.com>

Intellectual Property: The Company's patented Mosquito Magnet® technology is the result of more than 12 years of extensive scientific research. The Company has also developed the first-ever, EPA-registered attractant designed specifically for the Asian Tiger Mosquito – Lurex3. The Company has also developed methods and devices for trapping insects -- including its patented CounterFlow™ technology. [Company Website]

Description: The Company studies the behavior of biting insects and manufactures biting insect abatement traps for consumer, commercial and government applications.

[Return to top](#)

**Prospector
Profile
07.0345**

AmeriChip International, Inc.

9282 General Drive, Suite 100
Plymouth, MI 48170
(905) 898-2646

NAICS		333992
Employees		7
Revenue	(mil)	\$0.13
Income	(mil)	(\$10.99)
Assets	(mil)	\$1.04
Liability	(mil)	\$2.64
(for the year ended 11/30/2006)		

Category: Audit Concerns

Event: Williams & Webster PS expressed doubts on AmeriChip International, Inc.'s ability to continue as a going concern due to its significant operating losses.

Intellectual Property: The Company relies on patents to protect its technology but also has unpatented proprietary technology. The Company relies on nondisclosure and other contractual provisions to protect proprietary technology. Currently, it has two patents granted and intends to file other patent applications for enhancements to the existing patents. [SEC Filing 10-KSB 03-07-07]

Description: The Company provides Laser Assisted Chip Control technology for use in manufacturing.

Officers: Marc Walther (Chair, Pres. & CEO); Thomas Schwanitz (CFO); Edward Rutkowski (VP & Dir.); Richard H. Rossmann (Dir.)

Auditor: Williams & Webster PS

Securities: Common Stock-Symbol ACHI.OB; OTC BB;
588,245,853 common shares outstanding as of February 28, 2007.

[Return to top](#)

**Prospector
Profile
07.0346**

Apton Corporation

8 Penn Center, 1628 JFK Blvd., Suite 2300
Philadelphia, PA 19103
(215) 218-4340

NAICS		325414
Employees		66
Revenue	(mil)	\$0.00
Income	(mil)	(\$65.49)
Assets	(mil)	\$6.78
Liability	(mil)	\$11.64
(for the year ended 12/31/2005)		

Category: IP Asset Sale

Event: The U.S. Bankruptcy Court for the District of Delaware approved the Amended Disclosure Statement explaining the Joint Liquidating Plan proposed by Apton Corporation and the Official Committee of Unsecured Creditors. Under the Liquidating Plan, the Plan Administrator will be authorized to liquidate the Debtor's remaining assets including intellectual property, collection of deposits and the return of sums currently escrowed with third parties, and miscellaneous physical assets.

Intellectual Property: As of April 17, 2006, the Company held 18 issued patents in the U.S., 6 regional patents, and 138 granted patents in foreign countries, and has pending patent applications and patent applications in preparation. The Company protects its technology through numerous U.S. and foreign patent filings, trademarks and trade secrets that it owns or license. The Company intends to continue using scientific expertise to pursue and patent new developments with respect to uses, compositions and factors to enhance its position in the field of gastrointestinal, pancreatic, NSCLC, breast and colorectal cancers. [SEC Filing 10-K 04-17-06]

Description: The Company is focused on the development and commercialization of pharmaceutical products for the treatment of cancer and gastrointestinal disease. The Company filed for Chapter 11 protection on May 23, 2006 with the Bankruptcy Court for the District of Delaware, case number 06-10510, before Judge Christopher S. Sontchi.

Officers: Patrick T. Mooney (Chair, Pres. & CEO); James F. Smith (SVP & CFO); Robert S. Basso (Dir.); Vincent D. Enright (Dir.); William A. Hasler (Dir.); Georges Hibon (Dir.); David H. Sachs (Dir.)

Auditor: Ernst & Young LLP

Attorneys: Michael G. Busenkell, Esq., at Eckert Seamans Cherin & Mellot, LLC; Wilmington, DE; (302) 425-0430

Securities: Common Stock Symbol APHT.PK; PNK;
67,056,428 common shares outstanding as of April 17, 2006.

[Return to top](#)

**Prospector
Profile
07.0347**

Access International, Inc.

3208 Commander Drive
Carrollton, TX 75006
(972) 407-6080

NAICS	561621
Employees	17
Revenue (mil)	\$1.50
Income (mil)	(\$3.36)
Assets (mil)	\$1.28
Liability (mil)	\$4.75
(for the year ended 12/31/2006)	

Category: Audit Concerns

Event: Hein & Associates LLP raised doubts on Access International, Inc.'s ability to continue as a going concern after auditing the Company's financial statements. The auditor noted that the Company has recurring losses from operations, resulting in continued dependence on access to additional external financing. If the Company is unable to generate profitable operations or raise additional capital, it may be forced to seek protection under federal bankruptcy laws.

Intellectual Property: The Company relies on a combination of patents, trade secrets, technology licenses, and other intellectual property rights. Historically, it has received 16 U.S. patents. During 2006, the Company sold 11 of its video patents but retains a royalty-free perpetual license to use the patents in its products. The Company currently owns 5 patents related to RFID technology and has 4 additional patents in various stages of prosecution. The Company has applied for registration of a number of trade and service marks, including Access Inc.TM, the Access Inc. (logo)TM, LANcam, ActiveTagTM, Onlinesupervisor.comTM, Prism VideoTM, LANcorderTM, AccessibilityTM, AccessPlugTM, and Asset ActivatorTM. [SEC Filing 10-KSB 03-02-07]

Description: The Company manufactures physical security and enterprise asset management systems that locate, identify, track, monitor, count, and protect people, property, and vehicles.

Officers: Richard C.E. Morgan (Chair); Allan Griebenow (Pres., CEO & Dir.); Allan L. Frank (VP, Sec. & CFO); Robert J. Bertoldi (Dir.); Paul J. Coleman, Jr. (Dir.); Robert F. Hussey (Dir.)

Auditor: Hein & Associates LLP

Securities: Common Stock-Symbol AXSI.OB; OTC BB;
27,437,111 common shares outstanding as of December 31, 2005.

[Return to top](#)

**Prospector
Profile
07.0348**

Brightec, Inc.

8C Pleasant Street, First Floor
South Natick, MA 01760
(508) 647-9710

NAICS		326113
Employees		3
Revenue	(mil)	\$0.13
Income	(mil)	(\$0.74)
Assets	(mil)	\$0.37
Liability	(mil)	\$1.04
(for the year ended 12/31/2005)		

Category: Audit Concerns

Event: Carlin, Charron and Rosen, LLP expressed doubt about Brightec, Inc.'s ability to continue as a going concern after auditing the Company's financial statements. The auditor pointed out that the Company has incurred losses since inception, has had negative cash flows from operations, and has a stockholders' deficit at December 31, 2005.

Intellectual Property: The Company's wholly-owned subsidiary, Brightec SA, owns all patents and trademarks used in the operation of its business. Brightec SA's base patent covers an optical filter process that is applicable to all types of luminescent prints (photographic, textile and decoration), as well as the products resulting from the implementation of this process. A European procedure patent has also been issued providing coverage in 14 principal countries as well as China, Mexico and Poland. A US patent covering Brightec SA's initial claim relating to its proprietary technology was issued in September 2003. Brightec SA's initial base patent application has been issued in a total of 22 countries and is pending in Brazil, Canada, and Japan. Brightec SA has registered its "Brightec" and "Be Brilliant" trademarks in more than 20 countries worldwide and intends to register other trademarks as they are introduced. [SEC Filing 10-KSB 06-08-06]

Description: The Company engages in the development, marketing, and sale of luminescent films incorporating luminescent or phosphorescent pigments.

Officers: Patrick Planche (Pres., CEO, Treas. & Dir.); David Geffen (Dir.)

Auditor: Carlin, Charron and Rosen, LLP

Securities: Common Stock-Symbol BRTE.OB; OTC BB;
100,000,000 common shares outstanding as of November 20, 2006.

[Return to top](#)

**Prospector
Profile
07.0349**

California News Tech

825 Van Ness Avenue, Suite 406-407
San Francisco, CA 94109
(415) 861-3421

NAICS 516110

Revenue	(mil)	\$0.08
Income	(mil)	(\$0.73)
Assets	(mil)	\$0.32
Liability	(mil)	\$0.22

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Jewell & Langsdale expressed doubts on California News Tech's ability to continue as a going concern due to its recurring losses from operations and net capital deficiency.

Intellectual Property: The Company owns the software used to create MediaSentiment™, which was purchased from Strategic Information Technology International, Inc. In July 2006, the Company received registered status by the US Patent and Trademark Office for the name Media Sentiment®. The Company has also registered several domain names, including: www.MediaSentiment.com, www.aHeadsUp.com, www.anUpperHand.com, www.PublicMemory.com, www.CaliforniaNewsTech.com, www.DNAshare.com, www.theBigMovers.com, www.eSibyl.com and www.eSibyl.com. Over the next 12 months, it plans to seek federally registered trademarks for intellectual property, including the logos associated with MediaSentiment™ and the names and logos associated with HeadsUp and Upper Hand, the thumbs up and thumbs down symbols, and the user interface for HeadsUp. The Company has also registered with the Copyright Office, the copyrights for the caption work "Stock Performance vs Sentiment - Cisco," which is a chart plotting the stock performance along with the media sentiment at various stock performance values. [SEC Filing 10-K 02-28-07]

Description: The Company provides online access to news media analysis for a subscription fee in the United States.

Officers: Marian Munz (Pres., CEO & Dir.); William White (CFO)

Auditor: Jewell & Langsdale

Securities: Common Stock-Symbol CNEW.OB; OTC BB;
3,640,440 common shares outstanding as of December 31, 2006.

[Return to top](#)

**Prospector
Profile
07.0350**

Dalrada Financial Corp.

9449 Balboa Ave., Suite 210
San Diego, CA 92123
(858) 451-6120

NAICS		236000
Employees		75
Revenue	(mil)	\$70.38
Income	(mil)	\$2.62
Assets	(mil)	\$14.70
Liability	(mil)	\$36.32
(for the year ended 6/30/2006)		

Category: Loss/Deficit

Event: Dalrada Financial Corp. reported a net loss of \$679,000, despite an increase in total revenues to \$58.94 million for the second quarter ended Dec. 31, 2006, compared with a net income of \$3.42 million on total revenues of \$17.83 million for the second quarter ended Dec. 31, 2005. For the six months ended Dec. 31, 2006, the Company had a net loss of \$3.91 million on total revenues of \$95.9 million, as compared with a net income of \$3.15 million on total revenues of \$29.86 million for the same period in 2005. As of Dec. 31, 2006, the Company listed \$21.83 million in total assets, \$46.76 million in total liabilities, and \$550,000 in minority interests, resulting to \$25.47 million in total stockholders' deficit. The Company's balance sheet also showed strained liquidity with \$13.53 million in total current assets available to pay \$42.04 million in total liabilities coming due within the next 12 months.

Intellectual Property: The Company has obtained U.S. registration for several trade names or trademarks, including ColorBlind, Photomotion Images, MedicalHR, CallCenterHR, SourceOne Group, and The Benefits Bank. The Company relies on a combination of trade secret, copyright and trademark protection, and non-disclosure agreements to protect proprietary rights. Software products related to imaging operations are copyrighted. The Company protects software source code as trade secrets and makes proprietary source code available to OEM customers only under limited circumstances and specific security and confidentiality constraints. The Company also holds the patent for Photomotion. [SEC Filing 10-KSB 10-16-06]

Description: The Company, formerly known as Imaging Technologies Corp., provides financial services to small and medium-sized businesses.

Officers: Brian Bonar (Chair & CEO); David Lieberman (Chief Acctg. Officer); Eric W. Gaer (Dir.); Stanley Hirschman (Dir.); Richard H. Green (Dir.); Paul F. Muscenti (Dir.); Robert T. Baker (Dir.); Jim Ellis (Dir.)

Auditor: Pohl, McNabola, Berg & Company, LLP

Securities: Common Stock Symbol DFCO.OB; OTC BB; 4,970,066 common shares outstanding as of February 15, 2007.

[Return to top](#)

**Prospector
Profile
07.0351**

Dobson Communications Corp.

14201 Wireless Way
Oklahoma City, OK 73134
(405) 529-8500

NAICS		517212
Employees		2,500
Revenue	(mil)	\$1,271.10
Income	(mil)	\$12.78
Assets	(mil)	\$3,494.75
Liability	(mil)	\$3,303.17
(for the year ended 12/31/2006)		

Category: Low Rating

Event: On March 9, 2007, Moody's Investors Service affirmed the rating of Caa1, LGD5, 89%, on Dobson Communications Corp.'s senior unsecured notes. The rating agency also affirmed its SGL-1 speculative grade liquidity rating on the Company. The rating outlook remains stable. The rating actions follows the decision of American Cellular Corp. not to issue \$425 million in senior unsecured notes to partially fund the full redemption of its \$900 million 10% senior unsecured notes issue. Instead, the American Cellular Corp. would increase the size of its planned senior secured bank facility by \$200 million, to \$1.05 billion, and leave approximately \$225 million of the 10% senior unsecured notes outstanding.

Intellectual Property: The Company markets its services under the DOBSON CELLULAR SYSTEMS® and CELLULARONE® trademarks. It also licenses the CELLULARONE® name to nine other wireless communications providers. [SEC Filing 10-K 02-28-07]

Description: The Company provides digital voice, data, and other wireless communications services to its customers primarily through global system for mobile communications (GSM), general packet radio service, and enhanced data for GSM evolution networks.

Officers: Everett R. Dobson (Chair); Steven P. Dussek (CEO & Dir.); Bruce R. Knooihuizen (EVP & CFO); Timothy J. Duffy (SVP & Chief Technical Officer); R. Thomas Morgan (SVP & CIO); Ronald L. Ripley (SVP & Gen. Counsel); Frank Franzese (SVP-Sales); Thomas A. Coates (VP-Corporate Dev't); Thomas K. Roberts (Chief Mktg. Officer); Richard D. Sewell, Jr. (Treas.); Stephen T. Dobson (Sec. & Dir.); Trent LeForce (Controller & Asst. Sec.); Mark S. Feighner (Dir.); Fred J. Hall (Dir.); Justin L. Jaschke (Dir.); Albert H. Pharis, Jr. (Dir.); Robert A. Schriesheim (Dir.)

Auditor: KPMG LLP

Securities: Common Stock Symbol DCEL; NasdaqGM;
171,144,716 common shares outstanding as of February 21, 2007.

[Return to top](#)

**Prospector
Profile
07.0352**

Elan Corporation PLC

Treasury Building, Lower Grand Canal Street
Dublin, Ireland 2
353-1-709-4000

NAICS		541710
Employees		1,734
Revenue	(mil)	\$560.40
Income	(mil)	(\$267.30)
Assets	(mil)	\$2,746.30
Liability	(mil)	\$2,661.20
(for the year ended 12/31/2006)		

Category: Loss/Deficit

Event: Elan Corporation PLC reported a net loss for the year ended December 31, 2006 of \$267.3 million on revenues of \$560.4 million. This is considerably lower than the net loss reported last year of \$383.2 million on revenues of \$490.3 million. The continues losses has resulted to an accumulated deficit of \$5,255.6 million as of December 31, 2006. The Company also used cash for operating activities of \$238.7 million, roughly the same pace as last year's \$238.7 million.

Intellectual Property: The Company owns or licenses a number of patents in the United States and other countries. These patents cover pharmaceutical active ingredients; pharmaceutical formulations; and product manufacturing processes. Tysabri is covered by a number of pending patent applications and issued patents in the United States and many other countries. The Company has a basic US patent for Tysabri, which expires in 2014, subject to any available patent term extensions. The fundamental US patent covering the use of Prialt to produce analgesia expires in 2011. The basic US patent for Maxipime expires in March 2007 but two US patents covering Maxipime formulations may provide patent protection until February 2008. The primary patents covering its NanoCrystal technology expire in the United States in 2011. In addition, the Company has a large patent estate resulting from Alzheimer's disease research. The Company's products are sold around the world under brand name, logo and product design trademarks that are considered to be of material importance. [SEC Filing 20-F 02-28-07]

Description: The Company is engaged in neuroscience-based biotechnology that is focused on discovering, developing, manufacturing and marketing advanced therapies in neurology, autoimmune diseases, and severe pain.

Officers: Kelly Martin (Pres. & CEO); Paul Breen (EVP); Richard T. Collier (EVP & Gen. Counsel); Shane Cooke (EVP & CFO); William Daniel (EVP & Sec.)

Auditor: KPMG LLP

Securities: Common Stock-Symbol ELN; NYSE;
467,485,612 common shares outstanding as of December 31, 2006.

[Return to top](#)

**Prospector
Profile
07.0353**

Emisphere Technologies, Inc.

765 Old Saw Mill River Rd.
Tarrytown, NY 10591
(914) 347-2220

NAICS		325412
Employees		118
Revenue	(mil)	\$7.26
Income	(mil)	(\$41.77)
Assets	(mil)	\$28.09
Liability	(mil)	\$34.20
(for the year ended 12/31/2006)		

Category: Loss/Deficit

Event: Emisphere Technologies, Inc. reported a net loss for the year ended December 31, 2006 of \$41.766 million on revenues of \$7.259 million, compared to last year's net loss of \$18.051 million on revenues of \$3.540 million. The Company has a stockholder's deficit of \$6.106 million and accumulated deficit of \$392.372 million as of December 31, 2006.

Intellectual Property: The Company has patents and patent applications for delivery agents currently used in conjunction with insulin, heparin, LMWH, sCT, PTH 1-34, rhGH and numerous other pharmaceutical and biotechnology products. As of December 31, 2006, the Company has 90 granted patents in the United States and has other patents issued or applications pending in various countries around the world. In addition, the Company has 84 patent applications relating to drug delivery technology pending in the United States. It also has pursued strategic international protection with approximately 140 patents and 353 patent applications pending internationally in a total of 45 different countries. There are also nine trademarks currently granted by the U.S. Patent and Trademark office and 19 trademarks granted by foreign country patent offices. One US trademark and 11 international trademarks are pending. They include EMISPHERE®, Elaprin™ (oral heparin), The Emisphere Logo, and eligen®. [SEC Filing 10-K 03-05-07]

Description: The Company, formerly known as Clinical Technologies Associates, Inc., is a biopharmaceutical company specializing in the oral delivery of therapeutic macromolecules and other compounds that are not deliverable by oral means.

Officers: Michael M. Goldberg (Chair & CEO); William Rumble (Controller & Prin. Acctg. Officer); Elliot M. Maza (CFO); Howard M. Paek (Dir.); Mark H. Rachesky (Dir.); Michael Weiser (Dir.); Stephen K. Carter (Dir.); John D. Harkey, Jr. (Dir.)

Auditor: PricewaterhouseCoopers LLP

Securities: Common Stock-Symbol EMIS; NasdaqNM;
28,233,304 common shares outstanding as of November 2, 2006.

[Return to top](#)

**Prospector
Profile
07.0354**

Furniture Brands International, Inc.

101 South Hanley Road
St. Louis, MO 63105
(314) 863-1100

NAICS		337000
Employees		13,800
Revenue	(mil)	\$2,418.18
Income	(mil)	\$55.06
Assets	(mil)	\$1,558.20
Liability	(mil)	\$647.49
(for the year ended 12/31/2006)		

Category: Covenant Problems

Event: Furniture Brands International, Inc. disclosed in a regulatory filing with the SEC that it may not be in compliance with the financial covenants in its revolving credit facility and note purchase agreement as of March 31, 2007. The Company is currently in negotiations with both lending groups to amend the agreements to include less restrictive covenants. The negotiations could result in economic concessions to the lending groups including increased costs, reduction in the size of the revolving credit facility or other modifications to the terms and conditions of the agreements. At December 31, 2006, loans outstanding under the revolving credit facility consisted of \$160.0 million based on the adjusted Eurodollar rate currently at an annual interest rate of 6.10%. The Note Purchase Agreement allowed for the issuance and sale of \$150.0 million of 6.83% senior notes.

Intellectual Property: The Company utilizes trademarks and trade names extensively to promote brand loyalty among consumers. The Company views such trademarks and tradenames as valuable assets and aggressively protects trademarks and trade names. The Company's principle trademarks and tradenames are: Broyhill, Lane, Laneventure, Thomasville, Henredon, Drexel Heritage, Maitland-Smith, Hickory Chair, Pearson, HBF, Founders Furniture, Vignettes, and Creative Interiors. [SEC Filing 10-K 03-01-07]

Description: The Company designs, manufactures, sources, markets and distributes a full-line of wood and upholstered furniture through its operating subsidiaries Broyhill Furniture Industries, Inc.; Lane Furniture Industries, Inc.; Thomasville Furniture Industries, Inc., and HDM Furniture Industries, Inc.

Officers: Wilbert G. Holliman (Chair & CEO); John T. Foy (Pres., COO & Dir.); Denise L. Ramos (SVP & CFO); Lynn Chipperfield (SVP & Gen. Counsel); Mary E. Sweetman (SVP-HR); Steven W. Alstadt (Controller & Chief Acctg. Officer)

Auditor: KPMG LLP

Securities: Common Stock Symbol FBN; NYSE;
48,336,252 common shares outstanding as of January 31, 2007.

[Return to top](#)

**Prospector
Profile
07.0355**

GTC Biotherapeutics, Inc.

175 Crossing Blvd.
Framingham, MA 01702
(508) 620-9700

NAICS		325414
Employees		130
Revenue	(mil)	\$6.13
Income	(mil)	(\$35.35)
Assets	(mil)	\$73.24
Liability	(mil)	\$35.28
(for the year ended 12/31/2006)		

Category: Loss/Deficit

Event: GTC Biotherapeutics, Inc. reported a net loss of \$35.345 million net loss on sales of \$6.128 million for the year ended December 31, 2006. This is higher than the reported net loss last year of \$30.112 on revenues of \$4.152 million. As a result, the Company had an accumulated deficit of \$245.129 million as of December 31, 2006. The Company also used cash for operating activities totalling \$24.630 million for fiscal year 2006.

Intellectual Property: The Company holds 25 issued or allowed U.S. patents and 180 corresponding foreign patents. The Company received a U.S. patent, with claim coverage for the production of therapeutic proteins in the mammary glands of transgenic mammals. In accordance with ongoing research and development efforts, the Company has 56 pending U.S. patent applications and 184 corresponding foreign applications covering relevant and newly developed portions of its transgenic technology. Several of these pending applications are included in various cross-licensing or out-licensing arrangements with other companies. Recently issued U.S. patents provides claim coverage for protein purification from the milk of transgenic animals, the production of monoclonal and assembled antibodies at commercial levels in the milk of transgenic mammals, the production of recombinant antithrombin in the milk of transgenic goats and the production of prolactin in the milk of transgenic animals. [SEC Filing 10-K 03-07-07]

Description: The Company is involved in the development and production of human therapeutic proteins through transgenic technology.

Officers: Geoffrey F. Cox (Chair, Pres. & CEO); John B. Green (SVP, Treas. & CFO); Robert W. Baldrige (Dir.); Kenneth A. Bauer (Dir.); Francis J. Bullock (Dir.); James A. Geraghty (Dir.); Michael J. Landine (Dir.); Pamela W. McNamara (Dir.); Marvin L. Miller (Dir.); Alan W. Tuck (Dir.)

Auditor: PricewaterhouseCoopers LLP

Securities: Common Stock-Symbol GTCB; NasdaqGM;
77,577,355 common shares outstanding as of March 1, 2007.

[Return to top](#)

**Prospector
Profile
07.0356**

Headliners Entertainment Group, Inc.

One Exchange Place, Suite 1000-19
Jersey City, NJ 07302
(973) 685-5989

NAICS		711190
Employees		329
Revenue	(mil)	\$5.69
Income	(mil)	\$14.47
Assets	(mil)	\$8.62
Liability	(mil)	(\$49.85)

(for the year ended 12/31/2005)

Category: Bankruptcy

Event: Headliners Entertainment Group, Inc. filed for Chapter 11 protection on March 5, 2007, with the U.S. Bankruptcy Court for the District of New Jersey-Newark, case number 07-12947, before Judge Rosemary Gambardella.

Intellectual Property: The Company owns and operates comedy clubs utilizing the Rascals trademark. The Company also acquired six dance clubs that operate under one of the trade names: "Banana Joe's," "Margarita Mama's," "Red Cheetah," "Parrot Beach" and "Cactus Cafe." [SEC Filing 10-KSB 04-05-06]

Description: The Company, formerly known as Rascals International, Inc., owns and operates two Rascals Comedy Clubs in Montclair and Cherry Hill, New Jersey, and six dance clubs in Kentucky, Mississippi, Missouri, New Jersey, and Ohio.

Officers: Frank J. Orlando (CFO & Chief Restructuring Officer)

Auditor: Bagell, Josephs, Levine & Company LLC

Attorneys: Katherine Suplee, Esq.; Union, NJ; (908) 687-7080

Securities: Common Stock Symbol HLEG.OB; OTCBB;
158,564,854 common shares outstanding as of November 11, 2006.

Notes: The Company had total assets of \$3.44 million and total liabilities of \$15.57 million as of September 30, 2006.

[Return to top](#)

**Prospector
Profile
07.0357**

Human Genome Science, Inc.

14200 Shady Grove Road
Rockville, MD 20850
(301) 309-8504

NAICS		541710
Employees		770
Revenue	(mil)	\$25.76
Income	(mil)	(\$251.17)
Assets	(mil)	\$1,149.67
Liability	(mil)	\$935.75
(for the year ended 12/31/2006)		

Category: Loss/Deficit

Event: Human Genome Science, Inc. reported a net loss of \$251.173 million on revenues of \$25.755 million for the fiscal year ended December 31, 2006. The Company had net losses of \$239.439 million and \$242.898 million in fiscal years 2005 and 2004, respectively. As result of its continuing losses, the Company reported an accumulated deficit of \$1,620.381 million as of December 31, 2006. The Company also used cash for operating activities totalling \$146.833 million for the year ended December 31, 2006.

Intellectual Property: The Company pursues patents to protect intellectual property and has developed a significant intellectual property portfolio. As of February 1, 2007, the Company has 560 issued U.S. patents covering genes, proteins and antibodies, and has filed U.S. patent applications covering many more human genes, the proteins they encode, antibodies and proprietary technologies. [SEC Filing 10-K 02-28-07]

Description: The Company, develops protein and antibody drugs to treat diseases, such as hepatitis C, lupus, anthrax disease, cancer, rheumatoid arthritis, and HIV/AIDS primarily in the United States.

Officers: Argeris N. Karabelas, Ph.D. (Chair); H. Thomas Watkins (Pres. & CEO); Timothy C. Barabe (SVP & CFO); Richard J. Danzig (Dir.); Jürgen Drews, M.D. (Dir.); Augustine Lawlor (Dir.); Kevin P. Starr (Dir.); Tuan Ha-Ngoc (Dir.); Max Link, Ph.D. (Dir.); Robert C. Young, M.D. (Dir.)

Auditor: Ernst & Young LLP

Securities: Common Stock-Symbol HGSI; NasdaqGM;
134,015,286 common shares outstanding as of January 31, 2007.

[Return to top](#)

**Prospector
Profile
07.0358**

Innuity, Inc.

8644 154th Avenue NE
Redmond, WA 98052
(425) 497-9909

NAICS		518111
Employees		176
Revenue	(mil)	\$21.68
Income	(mil)	(\$8.47)
Assets	(mil)	\$7.34
Liability	(mil)	\$10.92
(for the year ended 12/31/2006)		

Category: Audit Concerns

Event: Hansen, Barnett & Maxwell PC expressed doubt on Innuity, Inc.'s ability to continue as a going concern after auditing its financial statements for the year ended December 31, 2006. The auditor states that the Company has an accumulated deficit, has suffered losses from operations, has negative cash flows from operating activities, has negative working capital and a capital deficiency.

Intellectual Property: The Company relies on a combination of trademark, copyright and trade secret laws in the U.S. and other jurisdictions to protect proprietary technology and brand. It also enters into confidentiality and invention assignment agreements with employees and consultants, and confidentiality agreements with other third parties, and rigorously control access to proprietary technology. The Company does not currently have any patents or pending patent applications. However, it has filed and received notice of allowance for trademarks "Innuity" and "Small is the new big" and has filed a U.S. federal trademark application for "LeadConnect." The Company has received a U.S. registered federal trademark for "Vista" and its unregistered trademarks including Innuity Velocity, FreeStarter.com, Jadeon, Merchant Partners, Optify and 10x Marketing. [SEC Filing 10-KSB 03-06-07]

Description: The Company engages in the design, acquisition, and integration of applications to deliver solutions for small business in the United States. Its Internet technology is based on an on-demand model that allows small businesses to interact with customers, business partners, and vendors.

Officers: John Wall (Chair & CEO); John Dennis (Pres.); Bob Bench (CFO); Marvin Mall (COO); Shivonne Byrne (CMO)

Auditor: Hansen, Barnett & Maxwell PC

Securities: Common Stock-Symbol INNU.OB; OTCBB;
21,388,517 common shares outstanding as of February 23, 2007.

[Return to top](#)

**Prospector
Profile
07.0359**

Insmed, Inc.

8720 Stony Point Parkway, Suite 200
Richmond, VA 23235
(804) 565-3000

NAICS		541710
Employees		85
Revenue	(mil)	\$0.13
Income	(mil)	(\$40.93)
Assets	(mil)	\$22.87
Liability	(mil)	\$12.34
(for the year ended 12/31/2005)		

Category: Restructuring

Event: Insmed, Inc. has restructured its operations as a result of its litigation settlement with Tercica, Inc. and Genentech, Inc. The Company expects to reduce its work force by about 34%, and eliminate its sales and marketing group. It will also scale back production at its Boulder, Colorado, manufacturing plant to reflect the reduced drug product requirement.

Intellectual Property: The Company holds 28 United States patents relating to the composition, production, antibodies and methods of use for IPLEX and rhIGFBP-3. As part of the ongoing development of IPLEX, INSM-18 and rhIGFBP-3, the Company has filed patent applications related to new production methods, improved formulations, new medical uses and new dosing regimens in the United States and in many of the major international pharmaceutical markets. In addition, foreign counterparts to the U.S. patents have been issued in the major pharmaceutical markets, such as Europe, Canada and Japan. As part of its business strategy, the Company plans to license intellectual property which may be important to the development and commercialization of its products. [SEC Filing 10-K 03-06-06]

Description: The Company engages in the discovery and development of drug candidates for the treatment of metabolic diseases and endocrine disorders.

Officers: Geoffrey Allan (Chair, Pres., & CEO); Ronald D. Gunn (EVP & COO); Philip J. Young (EVP-Commercial Operations & Chief Business Officer); Kenneth Attie (VP-Medical Affairs); Andreas Sommer (Chief Scientific Officer); Kevin P. Tully (CFO); Kenneth G. Condon (Dir.); Graham K. Croke (Dir.); Steinar J. Engelsen (Dir.); Melvin Sharoky (Dir.); Randall W. Whitcomb (Dir.)

Auditor: Ernst & Young LLP

Securities: Common Stock Symbol INSM; NasdaqGM;
100,268,054 common shares outstanding as of November 1, 2006.

[Return to top](#)

**Prospector
Profile
07.0360**

iSECUREtrac Corporation

5078 South 111th Street
Omaha, NE 68137
(402) 537-0022

NAICS		344220
Employees		82
Revenue	(mil)	\$8.06
Income	(mil)	(\$5.45)
Assets	(mil)	\$12.65
Liability	(mil)	\$19.59
(for the year ended 12/31/2006)		

Category: Loss/Deficit

Event: iSECUREtrac Corporation posted a net loss of \$5,451,636 on revenues of \$8,063,843 for the fiscal year ended December 31, 2006, as compared with a net loss of \$3,873,908 on revenues of \$5,589,783 for the same period in 2005. As of December 31, 2006, the Company's balance sheet showed \$12,653,536 in total assets and \$19,590,821 in total liabilities, resulting to \$6,937,285 in stockholders' deficit and \$61,898,373 in accumulated deficit.

Intellectual Property: The Company has been issued four patents to date by the United States Patent Office for an "Apparatus and Method for Continuous Electronic Monitoring and Tracking of Individuals," "Apparatus and Method for Continuous Electronic Monitoring and Tracking of Individuals," "Antenna Orientation Maintaining System in a System for Tracking Individuals and Method of Use," and "Antenna Orientation Maintaining System in a System for Tracking Individuals and Method of Use." It has also been issued patent rights in Australia. The Company has been granted a non-exclusive software license from SiRF Technology, Inc. to embed SiRF's patented GPS technology into its products. The Company asserts common law copyright and statutory trade secret protection to its proprietary software. Its logo, the words "tracNET24", "iSECUREtrac", and the word "iSecureTrack" are registered trademarks. [SEC Filing 10-KSB 03-12-07]

Description: The Company develops, markets, and distributes electronic monitoring products, including those that employ global positioning satellite technology and related services to criminal justice and social service agencies for use in community supervision programs.

Officers: Roger J. Kanne (Chair); Peter A. Michel (Pres. & CEO); David G. Vana (CFO & Sec.); David G. Sempek (SVP-Technology & Chief Technology Officer); Edward J. Sempek (SVP-Operations & Business Development); Joseph A. Ethridge (Dir.); Robert W. Korba (Dir.); Bruce Leadbetter (Dir.); Ravi Nath (Dir.); Goh Yong Siang (Dir.)

Auditor: McGladrey & Pullen LLP

Securities: Common Stock Symbol ISEC.OB; OTCBB;
10,773,454 common shares outstanding as of March 6, 2007.

[Return to top](#)

**Prospector
Profile
07.0361**

IsoRay, Inc.

350 Hills Street, Suite 106
Richland, WA 99352
(509) 375-1202

NAICS		541710
Employees		53
Revenue	(mil)	\$1.99
Income	(mil)	(\$8.22)
Assets	(mil)	\$5.66
Liability	(mil)	\$2.77

(for the year ended 6/30/2006)

Category: Audit Concerns

Event: DeCoria, Maichel & Teague, P.S. expressed doubt about IsoRay, Inc.'s ability to continue as a going concern. IsoRay has generated material operating losses since inception and expects to continue to experience net operating losses. The Company's ability to continue as a going concern is subject to its ability to obtain necessary funding from outside sources.

Intellectual Property: The Company relies on a combination of patent, copyright and trademark laws, trade secrets, software security measures, license agreements and nondisclosure agreements to protect its proprietary rights. A patent for the Cesium separation and purification process was granted on May 23, 2000 by the U.S. Patent and Trademark Office (USPTO) under Patent Number 6,066,302, with an expiration date of May 23, 2020. The Company predecessor also filed for patent protection in four European countries under the Patent Cooperation Treaty. The Company's management believes that certain aspects of the IsoRay seed design and construction techniques are patentable innovations, and a patent application was filed on November 12, 2003. Certain methodologies regarding isotope production, separation, and seed manufacture are retained as trade secrets and are embodied in IsoRay's procedures and documentation. In June and July of 2004, three patent applications were filed relating to methods of deriving Cs-131 developed by IsoRay employees. The Company is currently working on developing and patenting additional methods of deriving Cs-131 and other isotopes. [SEC Filing 10-K 09-28-06]

Description: The Company, through its subsidiary, IsoRay Medical, Inc., engages in the production and development of brachytherapy seed for the treatment of prostate cancer and other solid cancer tumors in the United States and Europe.

Officers: Roger Girard (Chair, Pres. & CEO); Jonathan Hunt (CFO & Treas.); David Swanberg (EVP, Sec. & Dir.); Robert Kauffman (Dir.); Thomas LaVoy (Dir.); Stephen Boatwright (Dir.); Dwight Babcock (Dir.); Albert Smith (Dir.)

Auditor: DeCoria, Maichel & Teague, P.S.

Securities: Common Stock-Symbol ISRY.OB; OTC BB;
16,815,360 common shares outstanding as of February 7, 2007.

[Return to top](#)

**Prospector
Profile
07.0362**

Jag Media Holdings, Inc.

6865 SW 18th Street, Suite B-13
Boca Raton, FL 33433
(866) 300-7410

NAICS		516110
Employees		9
Revenue	(mil)	\$0.17
Income	(mil)	(\$3.64)
Assets	(mil)	\$0.58
Liability	(mil)	\$5.07
(for the year ended 7/31/2006)		

Category: Audit Concerns

Event: J.H. Cohn LLP raised doubts on Jag Media Holdings, Inc.'s ability to continue as a going concern due to its recurring losses and negative cash flows from operating activities.

Intellectual Property: The Company owns the trademarks JAG NOTES, AHEAD OF THE MONEY, STREETSIDE and STREETSIDE WITH DAN DORFMAN. Each of these trademarks were approved in 2002 and has a duration period of ten years, at which time each of the trademarks must be renewed or they will expire. The Company does not consider these trademarks to be material to its business. [SEC Filing 10-KSB 03-05-07]

Description: The Company provides financial and investment information through facsimile transmissions and a Web site.

Officers: Thomas J. Mazzarisi (Chair, CEO & Gen. Counsel); Stephen J. Schoepfer (Pres., COO, CFO & Sec.)

Auditor: J.H. Cohn LLP

Securities: Common Stock-Symbol JAGH.PK; PNK;
47,481,898 common shares outstanding as of February 14, 2007.

[Return to top](#)

**Prospector
Profile
07.0363**

Medirect Latino, Inc.

2101 West Atlantic Boulevard, Suite 101
Pompano Beach, FL 33069
(954) 321-3540

NAICS		325412
Employees		86
Revenue	(mil)	\$6.73
Income	(mil)	(\$26.01)
Assets	(mil)	\$2.94
Liability	(mil)	\$4.68
(for the year ended 6/30/2006)		

Category: Audit Concerns

Event: Berkovits, Lago & Company, LLP raised substantial doubt on Medirect Latino, Inc's ability to continue as a going concern due to the Company's recurring losses from operations.

Intellectual Property: MEDIRECT® is a registered trademark of MEDirect Latino, Inc. The Company also maintain several other registered trademarks, which are monitored on a regular basis. The Company has also registered its domain name: medirectlatino.org. [SEC Filing 10-KSB 03-06-07]

Description: The Company provides direct-to-consumer medical products to the Hispanic community in the United States and Puerto Rico.

Officers: Raymond J. Talarico (Chair & EVP); Debra L. Towsley (Pres. & Dir.); Charles W. Hansen, III (COO & Dir.)

Auditor: Berkovits, Lago & Company, LLP

Securities: Common Stock-Symbol MLTO.PK; PNK;
16,951,739 common shares outstanding as of June 30, 2006.

[Return to top](#)

**Prospector
Profile
07.0364**

Micromem Technologies, Inc.

777 Bay Street, Suite 1910,
Toronto, Ontario M5G 2E4
Canada
(416) 364-6513

NAICS		334418
Employees		8
Revenue	(mil)	\$0.01
Income	(mil)	(\$4.06)
Assets	(mil)	\$0.47
Liability	(mil)	\$0.91
(for the year ended 10/31/2006)		

Category: Audit Concerns

Event: Schwartz Levitsky Feldman LLP expressed doubt on Micromem Technologies, Inc.'s ability to continue as a going concern after auditing the Company's financial statements. The Company has incurred substantial losses to date. The auditor believes that it will be necessary to raise additional funds for the continuing development, testing and commercial exploitation of its technology. The sources of these funds has not yet been identified and there can be no certainty that sources will be available in the future.

Intellectual Property: The Company believes that protection of intellectual property is important to its ability to generate revenues from technology in the future. The Company has both issued patents and pending patent applications. It also enters into confidentiality and other agreements with third parties and employees to protect intellectual property and trade secrets. The Company intends to continue to actively pursue the protection of intellectual property. The Company's magnetic memory patent portfolio comprises three separate series of patents and patent applications: those covering technologies developed pursuant to research collaborations with the University of Toronto and OCE Inc.; those covering VEMRAM technology; and those covering HEMRAM technology. [SEC Filing 20-F 02-28-07]

Description: The Company develops magnetic random access memory (MRAM™) for aerospace/defense, sensors and RFID applications.

Officers: Salvatore Fuda (Chair); Joseph Fuda (Pres., CEO & Dir.); Dan Amadori (CFO); Cynthia Kuper (CTO); Manoj Pundit (Sec. & Dir.); Andrew Brandt (Dir.); David Sharpless (Dir.); Steven Van Fleet (Dir.); Larry Blue (Dir.); Oliver Nepomuceno (Dir.)

Auditor: Schwartz Levitsky Feldman LLP

Securities: Common Stock-Symbol MMTIF.OB; OTC BB;
69,191,299 common shares outstanding as of October 31, 2006.

[Return to top](#)

**Prospector
Profile
07.0365**

Oncolytics Biotech, Inc.

210, 1167 Kensington Crescent NW
Calgary, Alberta T2N 1X7
Canada
(403) 670-7377

NAICS 541710

Revenue	(mil)	\$0.00
Income	(mil)	(\$14.30)
Assets	(mil)	\$33.57
Liability	(mil)	\$2.77

(for the year ended 12/31/2006)

Category: Loss/Deficit

Event: Oncolytics Biotech, Inc. reported a net loss of \$14,297,524 for the year ended December 31, 2006, higher than the \$12,781,831 net loss reported in 2005. The Company's continued losses resulted in an accumulated deficit of \$65,030,066 as of December 31, 2006. The Company also used cash for operating activities of \$12,155,372 for the current fiscal year, higher than the \$11,052,462 used last year for operating activities.

Intellectual Property: The Company has been granted 19 U.S. patents, 5 Canadian patents and 3 European patents covering REOLYSIN® technology and modified herpes and adenoviruses.
[Company Website]

Description: The Company focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human cancers.

Officers: Brad Thompson, Ph.D. (Chair, Pres. & CEO); Doug Ball (CFO); Matt Coffey, Ph.D. (CSO); Karl Mettinger, M.D., Ph.D (CMO); George Gill, M.D. (SVP)

Auditor: Ernst & Young LLP

Securities: Common Stock-Symbol ONCY; NasdaqCM;
36,236,748 common shares outstanding as of December 31, 2005.

[Return to top](#)

**Prospector
Profile
07.0366**

Pinnacle Foods Group, Inc.

1 Old Bloomfield Avenue
Mt. Lakes, NJ 07046
(973) 541-6620

NAICS		311000
Employees		3,100
Revenue	(mil)	\$1,442.26
Income	(mil)	\$33.92
Assets	(mil)	\$1,792.08
Liability	(mil)	\$1,353.73
(for the year ended 12/31/2006)		

Category: Low Rating

Event: Moody's Investors Service lowered the rating of Pinnacle Foods Group, Inc.'s 8.25% senior subordinated notes from B3, LGD5, 85% to Caa2, LGD5, 84%. The rating agency also assigned Caa2 ratings to the \$400 million guaranteed senior unsecured notes and the \$250 million senior subordinated notes co-issued by its subsidiaries, Pinnacle Foods Finance LLC and Pinnacle Foods Finance Corp. The rating outlook is stable.

Intellectual Property: The Company owns a number of registered trademarks in the United States, Canada and other countries, including All Day Breakfast®, American Recipes®, Appian Way®, Candy Factory®, Casa Brava®, Casa Regina®, Celeste®, Country Kitchen®, Duncan Hines®, Food That's In Fashion®, Fun Frosters®, Grabwich®, Great Starts®, Grill Classics®, Hearty Bowls®, Hearty Hero®, Hungry-Man®, Hungry-Man Sports Grill®, Hungry-Man Steakhouse®, It's Good to be Full®, Lender's®, Log Cabin®, Lunch Bucket®, Magic Mini's®, Milwaukee's®, Moist Deluxe®, Mrs. Butterworth's®, Mrs. Paul's®, Only Mrs. Paul's®, Open Pit®, Oval's®, Signature Desserts®, Snack'mms®, Stackers®, Steakhouse Mix®, Syrup Dunk'ers®, The Original TV Dinner®, That's The Best Pickle I Ever Heard®, Treet®, Van de Kamp's®, Vlastic®, and Wiejske Wyroby®. The Company also owns a design trademark in the United States, Canada and other countries on the Vlastic stork. [SEC Filing 10-K 03-05-07]

Description: The Company, formerly known as Aurora Foods, produces grocery store staples and other food products.

Officers: C. Dean Metropoulos (Chair); William Toler (Pres.); Jeffrey P. Ansell (CEO); N. Michael Dion (EVP & CFO); Michael J. Cramer (EVP & Chief Admin. Officer); Craig Steeneck (EVP); William Darkoch (EVP); Stephen P. Murray (Dir.); Terry Peets (Dir.); Kevin G. O'Brien (Dir.); John W. Childs (Dir.); Adam L. Suttin (Dir.); Raymond B. Rudy (Dir.); David R. Jessick (Dir.); Rajath Shourie (Dir.)

Auditor: PricewaterhouseCoopers LLP

Securities: 100 common shares outstanding as of March 5, 2007.
8-1/4% senior subordinated notes due December 1, 2013

[Return to top](#)

**Prospector
Profile
07.0367**

Plastinum Corporation

c/o 245 Park Avenue
New York, New York 10167
(212) 792-4030

NAICS		326000
Employees		5
Revenue	(mil)	\$0.00
Income	(mil)	(\$1.97)
Assets	(mil)	\$0.05
Liability	(mil)	\$1.12
(for the year ended 12/31/2006)		

Category: Audit Concerns

Event: Russell Bedford Stefanou Mirchandani LLP raised doubts on Plastinum Corporation's ability to continue as a going concern due to its recurring losses from operations.

Intellectual Property: The Company owns a patented plastic blending technology that enables the production of homogeneous, commercially usable polymers from a varied stream of otherwise incompatible waste plastic or virgin plastic feedstock. The Plastinum Process is currently protected by U.S. Patent Number 6,107,400 and European Patent Number 92907183.5-2307. [SEC Filing 10-KSB 03-06-07]

Description: The Company owns and develops a patented and proprietary plastic blending technology, whereby various kinds of plastic can be mixed without the use of expensive chemical additives.

Officers: Jacques Mot (Chair, Pres. & CEO); Patrick Sulzer (COO); Robert Scherne (CFO); Marcel Rokegem (Dir.)

Auditor: Russell Bedford Stefanou Mirchandani LLP

Securities: Common Stock-Symbol
92,085,920 common shares outstanding as of February 21, 2007.

[Return to top](#)

**Prospector
Profile
07.0368**

Proxymed, Inc.

1854 Shackleford Court, Suite 200
Norcross, GA 30093
(770) 806-9918

NAICS		518210
Employees		336
Revenue	(mil)	\$65.46
Income	(mil)	(\$6.61)
Assets	(mil)	\$72.24
Liability	(mil)	\$44.82
(for the year ended 12/31/2006)		

Category: Audit Concerns

Event: Deloitte & Touche LLP expressed substantial doubt about Proxymed, Inc.'s ability to continue as a going concern after auditing the company's consolidated financial statements for the year ended December 31, 2006. The auditing firm pointed to the Company's declining revenues, recurring losses from operations, accumulated deficit and working capital deficit.

Intellectual Property: The Company relies on a combination of contracts, copyright, trademark and trade secret laws and other measures to protect proprietary information and technology. The Company has rights under a number of patent applications, in addition to rights under various trademarks and trademark applications. It has also acquired a number of copyright registrations covering various software and proprietary products. As part of confidentiality procedures, the Company generally enters into nondisclosure agreements with employees, distributors, certain vendors and customers, and limit access to and distribution of software, databases, documentation and other proprietary information. [SEC Filing 10-K 03-15-07]

Description: The Company, doing business as MedAvant Healthcare Solutions, operates as an electronic healthcare transaction company through its two segments, Transaction Services and Laboratory Communication Solutions.

Officers: James Hudak (Chair); John G. Lettko (Pres., CEO, & Dir.); Douglas J. O'Dowd (EVP, CFO, & Treas.); Peter E. Fleming III (EVP & Gen. Counsel); Lonnie W. Hardin (EVP-Operations); Adnane Khalil (EVP-Technology); Allison W. Myers (EVP-HR); Eric D. Arnson (EVP-Product & Business Development); Emily J. Pietrzak (EVP-Sales & Account Management); Teresa D. Stubbs (EVP-Mktg. & Corporate Communications); Edwin M. Cooperman (Dir.); Samuel R. Schwartz (Dir.); Eugene R. Terry (Dir.)

Auditor: Deloitte & Touche LLP

Securities: Common Stock Symbol PILL; NasdaqGM;
13,210,573 common shares outstanding as of March 9, 2007.

[Return to top](#)

**Prospector
Profile
07.0369**

Rigel Pharmaceuticals, Inc.

1180 Veterans Boulevard
South San Francisco, CA 94080
(650) 624-1100

NAICS		325412
Employees		152
Revenue	(mil)	\$33.47
Income	(mil)	(\$37.64)
Assets	(mil)	\$113.24
Liability	(mil)	\$26.01
(for the year ended 12/31/2006)		

Category: Loss/Deficit

Event: Rigel Pharmaceuticals, Inc. posted a net loss of \$37,637,000 on revenues of \$33,473,000 for the fiscal year ended December 31, 2006, as compared with a net loss of \$45,256,000 on revenues of \$16,526,000 in fiscal year 2005. The Company's balance sheet showed an increase in accumulated deficit from \$257,522,000 in 2005 to \$295,159,000 in 2006. The Company's total assets also decreased from \$147,668,000 in 2005 to \$113,240,000 in 2006.

Intellectual Property: The Company has over 160 pending patent applications and over 80 issued patents in the United States that are owned or exclusively licensed as well as pending corresponding foreign patent applications. The Company's policy is to file patent applications to protect technology, inventions and improvements to inventions that are commercially important to the development of its business. The Company seeks United States and international patent protection for a variety of technologies, including new screening methodologies and other research tools, target molecules that are associated with disease states identified in screens, and lead compounds that can affect disease pathways. The Company also intends to seek patent protection or rely upon trade secret rights to protect other technologies that may be used to discover and validate targets and that may be used to identify and develop novel drugs. The Company is also a party to various license agreements to use technologies in research and development. [SEC Filing 10-K 03-08-07]

Description: The Company engages in the discovery and development of small-molecule product candidates for the treatment of inflammatory diseases, cancer, and viral diseases.

Officers: James M. Gower (Chair & CEO); Raul R. Rodriguez (EVP & COO); Donald G. Payan (EVP, Chief Scientific Officer, & Dir.); Ryan D. Maynard (VP & CFO); Jean Deleage (Dir.); Bradford S. Goodwin (Dir.); Gary A. Lyons (Dir.); Walter H. Moos (Dir.); Hollings C. Renton (Dir.); Peter S. Ringrose (Dir.); Stephen A. Sherwin (Dir.)

Auditor: Ernst & Young LLP

Securities: Common Stock Symbol RIGL; NasdaqGM;
25,185,213 common shares outstanding as of February 27, 2007.

[Return to top](#)

**Prospector
Profile
07.0370**

Santarus, Inc.

10590 West Ocean Air Drive, Suite 200
San Diego, CA 92130
(858) 314-5700

NAICS		541710
Employees		338
Revenue	(mil)	\$49.24
Income	(mil)	(\$56.47)
Assets	(mil)	\$93.63
Liability	(mil)	\$47.32
(for the year ended 12/31/2006)		

Category: Loss/Deficit

Event: Santarus, Inc. reported a net loss for the year ended December 31, 2006 of \$56,466,328 on revenues of \$45,979,504, lower than the reported net loss of \$64,985,868 in 2005 and \$82,619,817 in 2004. As a result of its recurring losses, the Company has an accumulated deficit of \$259,733,794 as of December 31, 2006. The Company also used cash for operating activities totalling \$32,910,638 for the year ended December 31, 2006, as compared to the \$74,310,004 and \$47,396,366 in 2005 and 2004.

Intellectual Property: The Company does not currently own any issued patents. However, its Zegerid products incorporate patented technology that is exclusively licensed from the University of Missouri. In addition, the Company has applied and intends to continue to apply for patent protection for new technology whenever the benefit of patent protection outweighs the cost of obtaining patent protection. The Company has received U.S. and European Union trademark registration for its corporate name, Santarus®. It has also received trademark registration in the U.S., Canada and Japan and have applied for trademark registration in the EU for Zegerid®, and has applied for trademark registration for various other names. [SEC Filing 10-K 03-05-07]

Description: The Company focuses on therapies that treat gastrointestinal diseases and disorders. Its products are immediate-release formulations of omeprazole, a proton pump inhibitor.

Officers: David F. Hale (Chair); Gerald T. Proehl (Pres. & CEO); Debra P. Crawford (SVP & CFO); Daniel D. Burgess (Dir.); Michael E. Herman (Dir.); Michael G. Carter (Dir.); Ted W. Love, M.D. (Dir.); Kent Snyder (Dir.)

Auditor: Ernst & Young LLP

Securities: Common Stock-Symbol SNTS; NasdaqGM;
50,723,407 common shares outstanding as of February 15, 2007.

[Return to top](#)

**Prospector
Profile
07.0371**

Smurfit-Stone Container Corp.

150 North Michigan Avenue
Chicago, IL 60601
(312) 346-6600

NAICS		322130
Employees		25,200
Revenue	(mil)	\$7,157.00
Income	(mil)	(\$59.00)
Assets	(mil)	\$7,776.00
Liability	(mil)	\$6,112.00
(for the year ended 12/31/2006)		

Category: Low Rating

Event: Standard & Poor's Investors Service assigned its 'CCC+' senior unsecured debt rating on Smurfit-Stone Container Corp.'s proposed \$675 million senior unsecured notes due 2017 to be issued by the Company's wholly-owned subsidiary, Smurfit-Stone Container Enterprises, Inc. Credit analyst Pamela Rice said that the rating action reflects Standard & Poor's warning that an extended period of high fiber costs without additional price increases or a weaker-than-expected U.S. economy could hinder the expected Company's progress.

Intellectual Property: The Company actively pursues applications for patents on new inventions and designs and attempt to protect patents against infringement. Nevertheless, the Company believes that its success and growth are more dependent on the quality of products and relationships with customers than patent protection. It also holds or is licensed to use certain patents, licenses, trademarks and trade names on its products. [SEC Filing 10-K 02-28-07]

Description: The Company manufactures paperboard and paper-based packaging products in North America.

Officers: Patrick J. Moore (Chair & CEO); Steven J. Klinger (Pres. & COO); Charles A. Hinrichs (SVP & CFO); James E. Burdiss (SVP & CIO); Ronald D. Hackney (SVP-HR); Craig A. Hunt (SVP, Gen. Counsel, & Sec.); Paul K. Kaufmann (SVP & Controller)

Auditor: Ernst & Young LLP

Securities: Common Stock Symbol SSCC; NasdaqGS;
770 common shares outstanding as of February 28, 2007.
9.25% unsecured senior notes due February 1, 2008; 9.75% unsecured senior notes due February 1, 2011; 8.375% unsecured senior notes due July 1, 2012; 8.25% unsecured senior notes due October 1, 2012; 7.50% unsecured senior notes due June 1, 2013; 7.375% unsecured senior notes due July 15, 2014.

[Return to top](#)

**Prospector
Profile
07.0372**

Solutia, Inc.

575 Maryville Centre Drive
St. Louis, MI 63166
(314) 674-1000

NAICS		325100
Employees		5,700
Revenue	(mil)	\$2,905.00
Income	(mil)	\$11.00
Assets	(mil)	\$2,055.00
Liability	(mil)	\$3,472.00
(for the year ended 12/31/2006)		

Category: Section 363 Sales

Event: Solutia Inc. has reached a definitive agreement to sell Dequest, its water treatment phosphonates business, including certain liabilities to Thermphos Trading GmbH for \$67 million in cash, subject to a working capital adjustment. The parties will also enter into a lease and operating agreement under which Solutia will continue to operate the Dequest facility to produce Dequest products exclusively for Thermphos at Solutia's plant in Newport, Wales, in the U.K.

Intellectual Property: The Company owns a large number of patents that relate to a wide variety of products and processes and has pending a substantial number of patent applications. In addition, the Company is licensed under a small number of patents owned by others. It also owns a considerable number of established trademarks in many countries under which Solutia markets its products. These patents and trademarks, in the aggregate, are of material importance to the Company's operations. [SEC Filing 10-KSB 03-06-07]

Description: The Company makes and sells a variety of high-performance chemical-based materials. The Company filed for chapter 11 protection on December 17, 2003 with the Bankruptcy Court for the District of New York, Case Number 03-17949, before Judge Prudence Carter Beatty.

Officers: Jeffrey N. Quinn (Chair, Pres. & CEO); James M. Sullivan (SVP & CFO); Rosemary L. Klein (SVP, Sec. & Gen. Counsel); Paul N. Hatfield (Dir.); Robert H. Jenkins (Dir.); Philip R. Lochner (Dir.); Frank A. Metz, Jr. (Dir.); J. Patrick Mulcahy (Dir.); John B. Slaughter (Dir.); Sally G. Narodick (Dir.)

Auditor: Deloitte & Touche LLP

Attorneys: Richard M. Cieri, Esq. and Conor Reilly, Esq. of Kirkland & Ellis LLP; New York, NY; (212) 446-4800

Securities: Common Stock-Symbol SOLUQ.OB; OTC BB;
104,459,578 common shares outstanding as of February 28, 2007.

[Return to top](#)

**Prospector
Profile
07.0373**

Sun Healthcare Group, Inc.

18831 Von Karman Avenue, Suite 400
Irvine, CA 92612
(949) 255-7100

NAICS		623110
Employees		19,350
Revenue	(mil)	\$1,045.64
Income	(mil)	\$27.12
Assets	(mil)	\$621.42
Liability	(mil)	\$477.29
(for the year ended 12/31/2006)		

Category: Low Rating

Event: Standard & Poor's Investors Service assigned its 'CCC+' rating to Sun Healthcare Group, Inc.'s \$200 million subordinated notes. The rating outlook is stable. The Company will use the proceeds from its notes, in addition to \$121 million of net proceeds from an equity offering in December 2006, to finance the pending acquisition of Harborside Healthcare for \$628 million.

Intellectual Property: SunBridge®, SunDance®, CareerStaff Unlimited® and related names are registered trademarks of Sun Healthcare Group, Inc. and its subsidiaries. [SEC Filing 10-K 03-07-07]

Description: The Company provides long term, subacute, and special healthcare services primarily to the senior population in the U.S.

Officers: Richard K. Matros (Chair & CEO); L. Bryan Shaul (EVP & CFO); Tony M. Astorga (Dir.); Michael J. Foster (Dir.); Steven M. Looney (Dir.); Gregory S. Anderson (Dir.); Christian K. Bement (Dir.); Barbara B. Kennelly (Dir.); Milton J. Walters (Dir.)

Auditor: Ernst & Young LLP

Securities: Common Stock Symbol SUNH; NasdaqGM;
42,897,822 common shares outstanding as of February 27, 2007.

[Return to top](#)

**Prospector
Profile
07.0374**

Tapestry Pharmaceuticals, Inc.

4840 Pearl East Circle, Suite 300 W
Boulder, CO 80301
(303) 516-8500

NAICS		325412
Employees		31
Revenue	(mil)	\$0.00
Income	(mil)	(\$16.65)
Assets	(mil)	\$24.61
Liability	(mil)	\$2.70
(for the year ended 12/31/2006)		

Category: Loss/Deficit

Event: Tapestry Pharmaceuticals, Inc. reported a net loss for fiscal year ended December 31, 2006 of \$16.652 million, lower than the net loss of \$17.538 million in 2005 and \$24.174 million in 2004. As a result of its recurring losses, the Company has an accumulated deficit of \$123.914 million as of December 31, 2006.

Intellectual Property: The Company owns or has licensed issued patents and has applied for patents relating to oncology programs. The Company has applied for and will continue to apply for patents covering its technologies, processes and products. The Company also relies on trade secrets and other proprietary information to develop and protect its competitive position, some of which is not patented. [SEC Filing 10-K 03-07-07]

Description: The Company, together with its subsidiaries, develops therapies for the treatment of cancer.

Officers: Leonard P. Shaykin (Chair & CEO); Patricia Pilia (EVP & Dir.); Gordon Link (SVP & CFO); Bruce W. Fiedler (VP & Controller); Stephen K. Carter, M.D. (Dir.); George Gould (Dir.); Elliot M. Maza (Dir.); Arthur H. Hayes, Jr., M.D. (Dir.); Robert E. Pollack, Ph.D. (Dir.); Richard N. Perle (Dir.)

Auditor: Grant Thornton LLP

Securities: Common Stock-Symbol TPPH; NasdaqCM;
16,374,395 common shares outstanding as of February 27, 2007.

[Return to top](#)

**Prospector
Profile
07.0375**

Viropro, Inc.

8515 Place Devonshire, Suite 207
Montreal, Quebec H4P 2K1
Canada
(514) 731-8776

NAICS		541710
Employees		4
Revenue	(mil)	\$0.00
Income	(mil)	(\$4.44)
Assets	(mil)	\$1.56
Liability	(mil)	\$1.06
(for the year ended 11/30/2006)		

Category: Audit Concerns

Event: Stark Winter Schenkein & Co., LLP raised doubts on Viropro, Inc.'s ability to continue as a going concern due to its recurring loss from operations.

Intellectual Property: The Company acquired licenses to patented technologies related to the production of therapeutic proteins and human growth factors from Immuno Japan, Inc. On October 26, 2006, Viropro has signed a second agreement with the National Research Council-Biotechnology Research Institute (NRC-BRI) for the use of powerful inducible expression systems and production of the recombinant human interferon beta. The Company is also planning to sign new licenses with NRC-BRI in the near future for the production of other therapeutic human proteins including cytokines and monoclonal antibodies. [SEC Filing 10-KSB 02-28-07]

Description: The Company engages in the development and technology transfer of bio-generics through partnering with pharmaceutical companies in various countries.

Officers: Jean-Marie Dupuy (Pres., Sec., Treas. & Dir.); Gino Di Iorio (CFO); Claude Griscelli (Dir.); Prosper Azoulay (Dir.)

Auditor: Stark Winter Schenkein & Co., LLP

Securities: Common Stock-Symbol VPRO.OB; OTC BB;
32,492,621 common shares outstanding as of January 31, 2007.

[Return to top](#)

**Prospector
Profile
07.0376**

WR Grace & Company

7500 Grace Drive
Columbia, MD 21044
(410) 531-4000

NAICS		325000
Employees		6,500
Revenue	(mil)	\$2,826.50
Income	(mil)	\$18.30
Assets	(mil)	\$3,637.40
Liability	(mil)	\$4,187.20
(for the year ended 12/31/2006)		

Category: Loss/Deficit

Event: PricewaterhouseCoopers LLP expressed substantial doubt about the Company's ability to continue as a going concern. The Company and substantially all of its subsidiaries voluntarily filed for protection under Chapter 11 of the United States Bankruptcy Code on April 2, 2001.

Intellectual Property: Numerous patents and patent applications protect the Company's products, processes and manufacturing equipment. The Company also benefits from trade secrets, including know-how and other proprietary information relating to many products and processing technologies. The Company has registered the Grace® and the Grace® logo as trademark. It also markets engineered materials under the SYLOID®, SYLOJET®, TriSyl®, DARACLAR®, PERKASIL®, LUDOX®, PHONOSORB®, and SYLOBEAD® and other trademarks. [SEC Filing 10-K 03-02-07]

Description: The Company provides specialty chemicals and materials worldwide.

Officers: Paul J. Norris (Chair); Fred E. Festa (Pres., CEO & Dir.); Robert M. Tarola (SVP & CFO); W. Brian McGowan (SVP-Admin.); Mark A. Shelnitz (VP, Sec. & Gen. Counsel); John F. Akers (Dir.); H. Furlong Baldwin (Dir.); Ronald C. Cambre (Dir.); Marye Anne Fox (Dir.); Christopher J. Steffen (Dir.); John J. Murphy (Dir.); Mark Tomkins (Dir.); Thomas A. Vanderslice (Dir.)

Auditor: PricewaterhouseCoopers LLP

Securities: Common Stock-Symbol GRA; NYSE;
69,206,435 common shares outstanding as of January 31, 2007.

[Return to top](#)

**Prospector
Profile
07.0377**

Yarraman Winery, Inc.

700 Yarraman Road
Wybong, New South Wales
Australia 2333
(61) 2 6547-8118

NAICS		312130
Employees		19
Revenue	(mil)	\$1.83
Income	(mil)	(\$1.23)
Assets	(mil)	\$9.91
Liability	(mil)	\$7.36
(for the year ended 6/30/2006)		

Category: Audit Concerns

Event: Kabani & Company, Inc. raised substantial doubt about Yarraman Winery, Inc.'s ability to continue as a going concern after auditing the Company's consolidated financial statements for the year ended June 30, 2006. The auditor pointed to the Company's significant operating losses and insufficient capital. For the year ended June 30, 2006, the Company reported a \$1,216,766 comprehensive net loss on \$1,830,151 of net sales compared with a \$262,923 net loss on \$2,293,354 of net sales for the same period in fiscal 2005. At June 30, 2006, the Company's balance sheet showed \$9,909,698 in total assets, \$7,364,142 in total liabilities, and \$2,545,556 in total stockholders' equity.

Intellectual Property: All trademarks and intellectual property are licensed to the Company by Delta Dawn Pty Ltd. Delta Dawn advises that its material trademarks and intellectual property are protected in all material respects by the law of the governments which regulate the markets in which they are used. [SEC Filing 10-KSB 09-28-06]

Description: The Company, formerly known as Dazzling Investments, Inc., operates vineyards, and produces and distributes wine in New Zealand, Australia, U.S., Canada, Hong Kong, and throughout Europe.

Officers: Wayne Rockall (Pres. & CEO); John Laurence Wells (Sec. & CFO); William J. Stubbs (Dir.); William Bernard Middleton (Dir.); John J. Moroney (Dir.); Frank Starr (Dir.); Brian Johnston (Dir.)

Auditor: Kabani & Company, Inc.

Securities: Common Stock-Symbol YRMN.PK; PNK;
25,000,000 common shares outstanding as of January 31, 2007.

[Return to top](#)